For the quarter ending 2025-09-30, MAIA made $9,060,041 in revenue. -$8,903,189 in net income. Net profit margin of -98.27%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 6,357,290 | 3,110,867 | ||
| General and administrative expenses | 3,003,636 | 2,055,191 | ||
| Total operating expenses | 9,360,926 | 5,166,058 | ||
| Loss from operations | -9,360,926 | -5,166,058 | ||
| Interest income | 78,426 | 79,697 | ||
| Change in fair value of warrant liability | -379,311 | 260,602 | ||
| Loss on fair value of warrants over proceeds | - | 0 | ||
| Australian research and development incentives | - | 0 | ||
| Other (expense) income, net | 457,737 | -180,905 | ||
| Net loss | -8,903,189 | -5,346,963 | ||
| Net loss per share - basic | -0.27 | -0.18 | ||
| Net loss per share - diluted | -0.27 | -0.18 | ||
| Weighted average common shares outstanding - basic | 33,202,001 | 30,300,339 | ||
| Weighted average common shares outstanding - diluted | 33,202,001 | 30,300,339 | ||
MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. (MAIA)